Roche’s Elecsys Anti-SARS-CoV-2 S Receives the US FDA’s EUA to Detect Ab Against SARS-CoV-2 Spike Protein

Shots:

• The US FDA’s EUA follows the launch of the Elecsys Anti-SARS-CoV-2 S Ab test for markets accepting the CE Mark. The serology test can be used to measure the level of Abs in people who have been exposed to the SARS-CoV-2 virus
• The test has both a high NPA of 99.98% and PPA of 96.6%, 15days or later after diagnosis with a PCR test. The test may help identify recovering patients who could potentially be serum & plasma donors for developing treatments for COVID-19
• The test runs on Roche’s cobas e analyzers and is the latest addition to Roche’s diagnostic portfolio to help healthcare systems combat COVID-19 through testing in the laboratory and at the POC

Click here ­to­ read full press release/ article | Ref: Roche | Image: Forbes